Optimizing the timing of JAK1 inhibition preserves the anti-tumor efficacy of radioimmunotherapy in lung cancer by preventing T cell exhaustion

Abstract JAK1 inhibitors are widely used in hematologic malignancies and autoimmune diseases, their potential in combination with immunotherapy for solid tumors such as lung cancer is increasingly being recognized. The combination of radiotherapy and immunotherapy (radioimmunotherapy, iRT) has becom...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Zhiru Gao, Linlin Yang, Linlin Wang
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2026-07-01
Schriftenreihe:	Experimental Hematology & Oncology
Schlagworte:	Antitumor Lung cancer Radiotherapy Immunotherapy JAK1 inhibitor
Online-Zugang:	https://doi.org/10.1186/s40164-026-00802-3
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!